Article info

Original research
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

Authors

  1. Correspondence to Dr Yosuke Togashi; ytogashi1584{at}gmail.com
View Full Text

Citation

Kawashima S, Inozume T, Kawazu M, et al
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

Publication history

  • Accepted October 19, 2021
  • First published November 18, 2021.
Online issue publication 
November 18, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.